Sma. Abidi et al., THE INFLUENCE OF ANTIESTROGENS ON THE RELEASE OF PLASMINOGEN-ACTIVATOR (UPA) BY MDA-MB-231 AND MCF-7 BREAST-CANCER CELLS, Clinical & experimental metastasis, 16(3), 1998, pp. 235-241
Plasminogen activators are known to be involved in the metastatic spre
ad of breast cancer. In the present study we examined the effects of a
ntiestrogens [Analog II (1,1-dichloro-cis-2,3-diphenyl cyclopropane) (
AII), ICI-182,780 (ICI) and tamoxifen (TAM)], on the in vitro release
of uPA from estrogen receptor (ER)-positive MCF-7 (MCF) and ER-negativ
e MDA-MB-231 (MDA) human breast cancer cell Lines. Using a solid-phase
radioassay, uPA activity was found to be higher in the culture medium
from MDA cells compared to MCF cells. Aminocaproic acid, a specific p
lasmin inhibitor, produced a 50-60% reduction in the degradation of la
beled substrate, in the solid phase assay, using culture medium from b
oth cell lines, thus indicating that most of the proteolysis observed
was due to uPA-mediated plasmin generation from plasminogen. In the ab
sence of plasminogen, the enzyme activity was not detected in either t
he quantitative assay or by zymography. In MDA cells, uPA release was
not altered by any of the antiestrogens used alone or in the presence
of estradiol. In contrast, in MCF cells, ICI alone produced maximal in
hibition (40%) of enzyme release, while estradiol alone produced a 120
% increase in enzyme activity. When co-administered with estradiol, in
MCF cultures, each antiestrogen reduced enzyme activity to control le
vels. Substrate gel zymography revealed that the urokinase-type PA is
the predominant form of PA released by both cell lines. Comparison of
the activity of all three antiestrogens used in this study indicates t
hat ICI is the most potent inhibitor of enzyme activity in ER-positive
MCF cells. (C) 1998 Lippincott-Raven Publishers.